<DOC>
	<DOCNO>NCT00117208</DOCNO>
	<brief_summary>The purpose study determine medium term efficacy safety profile inhale mannitol , also additional therapy rhDNase ( pulmozyme ) . In particular , assess impact : lung function ; airway inflammation ; sputum microbiology ; exacerbation ; quality life ; adverse event ; exercise tolerance ; total cost hospital community care ; cost-effectiveness .</brief_summary>
	<brief_title>Comparison Inhaled Mannitol rhDNase Children With Cystic Fibrosis</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Mannitol</mesh_term>
	<criteria>Known diagnosis cystic fibrosis ( sweat test genotype ) Of either gender Aged 8 18 year Have baseline FEV1 &lt; 70 % predict normal value Currently take rhDNase least 4 week Currently active asthma , uncontrolled hypertension , colonise Burkholderia cepacia MRSA Listed transplantation Known intolerance mannitol , rhDNase bronchodilator</criteria>
	<gender>All</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>cystic fibrosis</keyword>
</DOC>